Switch theme
Sign up to access all valuation multiples
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
2011
10
Last FY Revenue n/a
Last FY EBITDA -$14.0M
$60.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, IBT achieved revenue of n/a and an EBITDA of -$14.0M.
IBT expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IBT valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$14.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$15.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$14.1M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, IBT's stock price is SEK 58 (or $6).
IBT has current market cap of SEK 777M (or $80.2M), and EV of SEK 586M (or $60.4M).
See IBT trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60.4M | $80.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, IBT has market cap of $80.2M and EV of $60.4M.
IBT's trades at n/a EV/Revenue multiple, and -4.3x EV/EBITDA.
Equity research analysts estimate IBT's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IBT's P/E ratio is not available.
See valuation multiples for IBT and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $80.2M | XXX | $80.2M | XXX | XXX | XXX |
| EV (current) | $60.4M | XXX | $60.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -4.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -5.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIBT's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.5M for the same period.
IBT's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IBT's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for IBT and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IBT acquired XXX companies to date.
Last acquisition by IBT was XXXXXXXX, XXXXX XXXXX XXXXXX . IBT acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was IBT founded? | IBT was founded in 2011. |
| Where is IBT headquartered? | IBT is headquartered in Sweden. |
| How many employees does IBT have? | As of today, IBT has 10 employees. |
| Who is the CEO of IBT? | IBT's CEO is Dr. Staffan Stromberg, PhD. |
| Is IBT publicy listed? | Yes, IBT is a public company listed on STO. |
| What is the stock symbol of IBT? | IBT trades under IBT B ticker. |
| When did IBT go public? | IBT went public in 2016. |
| Who are competitors of IBT? | Similar companies to IBT include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of IBT? | IBT's current market cap is $80.2M |
| Is IBT profitable? | Yes, IBT is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
